[S-8] Astria Therapeutics, Inc. Employee Benefit Plan Registration
Astria Therapeutics, Inc. filed a Form S-8 to register additional securities under its Second Amended and Restated 2015 Stock Incentive Plan (as amended), the 2015 Employee Stock Purchase Plan and the 2022 Inducement Stock Incentive Plan (as amended). The filing incorporates prior S-8 registrations by reference, attaches plan documents and counsel consents, and is signed by CEO Jill C. Milne and other officers and directors. The registrant is incorporated in Delaware and lists its principal executive offices in Boston, Massachusetts.
Astria Therapeutics, Inc. ha depositato un Form S-8 per registrare titoli aggiuntivi nell'ambito del Second Amended and Restated 2015 Stock Incentive Plan (as amended), del 2015 Employee Stock Purchase Plan e del 2022 Inducement Stock Incentive Plan (as amended). La dichiarazione incorpora per riferimento precedenti registrazioni S-8, allega i documenti dei piani e i consensi del consulente legale, ed 猫 firmata dall'amministratore delegato Jill C. Milne e da altri dirigenti e membri del consiglio. Il registrante 猫 costituito in Delaware e indica i suoi uffici esecutivi principali a Boston, Massachusetts.
Astria Therapeutics, Inc. present贸 un Form S-8 para registrar valores adicionales bajo el Second Amended and Restated 2015 Stock Incentive Plan (as amended), el 2015 Employee Stock Purchase Plan y el 2022 Inducement Stock Incentive Plan (as amended). El documento incorpora por referencia registros S-8 previos, adjunta los documentos de los planes y los consentimientos del asesor legal, y est谩 firmado por la directora ejecutiva Jill C. Milne y otros directivos y miembros del consejo. La sociedad est谩 constituida en Delaware y declara sus oficinas ejecutivas principales en Boston, Massachusetts.
Astria Therapeutics, Inc.電� 於旉皜 歃濌秾鞚� 霌彪頃橁赴 鞙勴暣 Form S-8鞚� 鞝滌稖頄堨姷雼堧嫟. 霌彪 雽�靸侅潃 Second Amended and Restated 2015 Stock Incentive Plan (as amended), 2015 Employee Stock Purchase Plan 氚� 2022 Inducement Stock Incentive Plan (as amended)鞛呺媹雼�. 鞝滌稖 靹滊電� 鞚挫爠 S-8 霌彪鞚� 彀胳“頃橃棳 韽暔頃橁碃 鞛堨溂氅�, 瓿勴殟 氍胳劀鞕� 氩曤 鞛愲 霃欖潣靹滊ゼ 觳秬頄堦碃 斓滉碃瓴届榿鞛�(CEO) Jill C. Milne 氚� 旮绊儉 鞛勳洂瓿� 鞚挫偓霌れ澊 靹滊獏頄堨姷雼堧嫟. 霌彪 氩曥澑鞚� Delaware鞐� 靹る霅橃柎 鞛堦碃 氤胳偓 靻岇灛歆�電� Boston, Massachusetts搿� 旮办灛霅橃柎 鞛堨姷雼堧嫟.
Astria Therapeutics, Inc. a d茅pos茅 un Form S-8 pour enregistrer des titres suppl茅mentaires au titre du Second Amended and Restated 2015 Stock Incentive Plan (as amended), du 2015 Employee Stock Purchase Plan et du 2022 Inducement Stock Incentive Plan (as amended). Le d茅p么t incorpore par r茅f茅rence les enregistrements S-8 ant茅rieurs, joint les documents des plans et les consentements du conseil juridique, et est sign茅 par la PDG Jill C. Milne ainsi que d'autres dirigeants et administrateurs. L'entit茅 d茅clarante est constitu茅e dans le Delaware et indique son si猫ge social principal 脿 Boston, Massachusetts.
Astria Therapeutics, Inc. hat ein Formular S-8 eingereicht, um zus盲tzliche Wertpapiere unter dem Second Amended and Restated 2015 Stock Incentive Plan (as amended), dem 2015 Employee Stock Purchase Plan und dem 2022 Inducement Stock Incentive Plan (as amended) zu registrieren. Die Einreichung nimmt fr眉here S-8-Registrierungen durch Verweis auf, f眉gt die Planunterlagen und Zustimmungen des Rechtsberaters bei und ist von CEO Jill C. Milne sowie weiteren F眉hrungskr盲ften und Direktoren unterzeichnet. Der Registrant ist in Delaware eingetragen und gibt seinen Hauptgesch盲ftssitz in Boston, Massachusetts an.
- Registers additional securities for the Second Amended and Restated 2015 Stock Incentive Plan (as amended), the 2015 Employee Stock Purchase Plan and the 2022 Inducement Stock Incentive Plan (as amended).
- Includes required exhibits such as plan documents, counsel opinion and auditor consent, supporting regulatory compliance for equity awards.
- No number of shares disclosed in the supplied text, so potential dilution from future grants cannot be assessed from this filing alone.
- Filer status check-boxes are not clearly interpretable from the provided content, leaving the registrant's filer classification ambiguous here.
Insights
TL;DR: Routine equity registration for employee compensation plans; governance impact is minor absent specifics on share counts or grant terms.
The filing formally registers additional securities for the company's existing equity compensation programs and includes the governing plan documents and counsel consents. From a governance perspective this is a standard compliance filing that preserves the company's ability to grant equity awards under approved plans. Material assessment is limited because the filing does not specify the number of shares being registered or the potential dilutive impact, preventing a full evaluation of shareholder effect.
TL;DR: Administrative S-8 filing enables future equity grants; neutral for valuation without disclosed share quantities or recent grant activity.
The registration covers the 2015 Stock Incentive Plan (as amended), the 2015 ESPP and the 2022 Inducement Plan, and incorporates prior S-8 filings by reference. Exhibits include plan text, counsel opinion and auditor consent. For investors, key missing data in this filing are the number of additional shares registered and any contemporaneous material grants, so the filing does not by itself indicate dilution or immediate financial impact.
Astria Therapeutics, Inc. ha depositato un Form S-8 per registrare titoli aggiuntivi nell'ambito del Second Amended and Restated 2015 Stock Incentive Plan (as amended), del 2015 Employee Stock Purchase Plan e del 2022 Inducement Stock Incentive Plan (as amended). La dichiarazione incorpora per riferimento precedenti registrazioni S-8, allega i documenti dei piani e i consensi del consulente legale, ed 猫 firmata dall'amministratore delegato Jill C. Milne e da altri dirigenti e membri del consiglio. Il registrante 猫 costituito in Delaware e indica i suoi uffici esecutivi principali a Boston, Massachusetts.
Astria Therapeutics, Inc. present贸 un Form S-8 para registrar valores adicionales bajo el Second Amended and Restated 2015 Stock Incentive Plan (as amended), el 2015 Employee Stock Purchase Plan y el 2022 Inducement Stock Incentive Plan (as amended). El documento incorpora por referencia registros S-8 previos, adjunta los documentos de los planes y los consentimientos del asesor legal, y est谩 firmado por la directora ejecutiva Jill C. Milne y otros directivos y miembros del consejo. La sociedad est谩 constituida en Delaware y declara sus oficinas ejecutivas principales en Boston, Massachusetts.
Astria Therapeutics, Inc.電� 於旉皜 歃濌秾鞚� 霌彪頃橁赴 鞙勴暣 Form S-8鞚� 鞝滌稖頄堨姷雼堧嫟. 霌彪 雽�靸侅潃 Second Amended and Restated 2015 Stock Incentive Plan (as amended), 2015 Employee Stock Purchase Plan 氚� 2022 Inducement Stock Incentive Plan (as amended)鞛呺媹雼�. 鞝滌稖 靹滊電� 鞚挫爠 S-8 霌彪鞚� 彀胳“頃橃棳 韽暔頃橁碃 鞛堨溂氅�, 瓿勴殟 氍胳劀鞕� 氩曤 鞛愲 霃欖潣靹滊ゼ 觳秬頄堦碃 斓滉碃瓴届榿鞛�(CEO) Jill C. Milne 氚� 旮绊儉 鞛勳洂瓿� 鞚挫偓霌れ澊 靹滊獏頄堨姷雼堧嫟. 霌彪 氩曥澑鞚� Delaware鞐� 靹る霅橃柎 鞛堦碃 氤胳偓 靻岇灛歆�電� Boston, Massachusetts搿� 旮办灛霅橃柎 鞛堨姷雼堧嫟.
Astria Therapeutics, Inc. a d茅pos茅 un Form S-8 pour enregistrer des titres suppl茅mentaires au titre du Second Amended and Restated 2015 Stock Incentive Plan (as amended), du 2015 Employee Stock Purchase Plan et du 2022 Inducement Stock Incentive Plan (as amended). Le d茅p么t incorpore par r茅f茅rence les enregistrements S-8 ant茅rieurs, joint les documents des plans et les consentements du conseil juridique, et est sign茅 par la PDG Jill C. Milne ainsi que d'autres dirigeants et administrateurs. L'entit茅 d茅clarante est constitu茅e dans le Delaware et indique son si猫ge social principal 脿 Boston, Massachusetts.
Astria Therapeutics, Inc. hat ein Formular S-8 eingereicht, um zus盲tzliche Wertpapiere unter dem Second Amended and Restated 2015 Stock Incentive Plan (as amended), dem 2015 Employee Stock Purchase Plan und dem 2022 Inducement Stock Incentive Plan (as amended) zu registrieren. Die Einreichung nimmt fr眉here S-8-Registrierungen durch Verweis auf, f眉gt die Planunterlagen und Zustimmungen des Rechtsberaters bei und ist von CEO Jill C. Milne sowie weiteren F眉hrungskr盲ften und Direktoren unterzeichnet. Der Registrant ist in Delaware eingetragen und gibt seinen Hauptgesch盲ftssitz in Boston, Massachusetts an.
FAQ
What plans does Astria Therapeutics (ATXS) register in this Form S-8?
Does the Form S-8 state how many shares are being registered for ATXS?
Who signed the registration statement for Astria Therapeutics (ATXS)?
Where is Astria Therapeutics incorporated and where are its principal offices?
Are supporting exhibits included with the filing for ATXS?
